Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127214 | 0.94 | AGTR1 (0.57) | AGTR1 | |
| SCHEMBL2126957 | 0.89 | TLR7 (0.44) | AGTR1 | |
| SCHEMBL13814579 | 0.86 | AGTR1 (0.58) | AGTR1 | |
| SCHEMBL2125878 | 0.85 | AGTR1 (0.58) | AGTR1 | |
| SCHEMBL2127380 | 0.84 | AGTR1 (0.58) | AGTR1 | |
| SCHEMBL4884809 | 0.84 | AGTR1 (0.53) | AGTR1 | |
| SCHEMBL2126682 | 0.83 | AGTR1 (0.45) | AGTR1 | |
| SCHEMBL2606670 | 0.82 | AGTR1 (0.55) | AGTR1 | |
| SCHEMBL4887978 | 0.81 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL13814622 | 0.81 | TLR7 (0.45) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513432-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513432-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513432-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2225210-B1 | Dual-acting benzoimidazole derivative and their use as antihypertensive agents | THERAVANCE INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2225210-B1 | Dual-acting benzoimidazole derivative and their use as antihypertensive agents | THERAVANCE INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2225210-A1 | DUAL-ACTING BENZOIMIDAZOLE DERIVATIVE AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009076288-A1 | DUAL-ACTING BENZOIMIDAZOLE DERIVATIVE AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076288-A1 | DUAL-ACTING BENZOIMIDAZOLE DERIVATIVE AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885 |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.